U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07391761) titled 'A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan' on Dec. 15, 2025.
Brief Summary: The purpose of this study is to evaluate:
* What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan?
* What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan?
* What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?
Study Start Date: Jan. 15
Study Type: OBSERVATIONAL
Condition:
Refractory Multiple Myeloma (RRMM)
Intervention:
DRUG: Non...